title: Effects of naloxone infusion on nocturnal prolactin secretion and Fos/FRA expression in pregnant rats.
abstract: Dopamine (DA) secreted by tuberoinfundibular dopaminergic (TIDA) neurons in the hypothalamus is the major inhibitory factor controlling prolactin (PRL) secretion from the anterior pituitary. Endogenous opioid peptides (EOPs), mainly the neuropeptide beta-endorphin, have a stimulatory influence on PRL secretion. During the first half of pregnancy in rats, PRL secretion is characterized by two daily surges, the nocturnal surge and the diurnal surge. We tested the hypothesis that EOPs are critical stimulatory factors in regulating the nocturnal PRL surge, possibly via inhibition of TIDA neuronal activity. Naloxone (NAL), an opioid antagonist, was continuously infused (0.2 mg/10 microL/min i.v.) during the expected time of the nocturnal PRL surge in day 8 pregnant rats. Radioimmunoassay (RIA) was used to measure plasma PRL levels, and the immunocytochemical (ICC) staining of Fos/FRA was performed to detect changes in transcriptional activity of neurons in the hypothalamus. ICC of tyrosine hydroxylase (TH), the rate-limiting enzyme for DA synthesis, was performed to visualize TIDA neurons in the arcuate nucleus. The results showed that the nocturnal surge of PRL was markedly delayed and dampened in NAL-treated rats (p < 0.01). The numbers of both Fos/FRA and (Fos/FRA)/TH dual-staining neurons increased in the arcuate nucleus following NAL treatment (p < 0.05 for both comparisons). These data indicate that EOPs are critical stimulatory factors for the nocturnal PRL surge and that the actions of EOPs are partially mediated via decreasing TIDA neuronal activity.
authors.affiliation: Department of Molecular and Integrative Physiology, University of Kansas Medical Center, Kansas City 66160, USA.
authors.forename: Y
authors.initials: Y
authors.lastname: Hou
authors.forename: J L
authors.initials: JL
authors.lastname: Voogt
mesh_terms: D000818:Animals; D002940:Circadian Rhythm; D005260:Female; D007033:Hypothalamus, Middle / Q000187:drug effects / Q000378:metabolism; D009270:Naloxone / Q000494:pharmacology*; D009292:Narcotic Antagonists / Q000494:pharmacology*; D010903:Pituitary Gland, Anterior / Q000378:metabolism; D011247:Pregnancy; D011388:Prolactin / Q000378:metabolism*; D016760:Proto-Oncogene Proteins c-fos / Q000378:metabolism*; D011863:Radioimmunoassay; D051381:Rats; D017207:Rats, Sprague-Dawley; D001615:beta-Endorphin / Q000502:physiology; D000099169:Fos-Related Antigen 1
chemical_list: D009270:Naloxone; D009292:Narcotic Antagonists; D011388:Prolactin; D016760:Proto-Oncogene Proteins c-fos; D001615:beta-Endorphin; D000099169:Fos-Related Antigen 1